<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-1146</journal-id>
<journal-title><![CDATA[Boletín médico del Hospital Infantil de México]]></journal-title>
<abbrev-journal-title><![CDATA[Bol. Med. Hosp. Infant. Mex.]]></abbrev-journal-title>
<issn>1665-1146</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Salud, Hospital Infantil de México Federico Gómez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-11462016000600405</article-id>
<article-id pub-id-type="doi">10.1016/j.bmhimx.2016.09.001</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Alveolar rhabdomyosarcoma: origin and prognostic implications of molecular findings]]></article-title>
<article-title xml:lang="es"><![CDATA[Rabdomiosarcoma alveolar: origen de los hallazgos moleculares e implicaciones pronósticas]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Eguía-Aguilar]]></surname>
<given-names><![CDATA[Pilar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Martínez]]></surname>
<given-names><![CDATA[Briceida]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Retana-Contreras]]></surname>
<given-names><![CDATA[Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Perezpeña-Diazconti]]></surname>
<given-names><![CDATA[Mario]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Hospital Infantil de México Federico Gómez Departmento de Patología Clínica y Experimental ]]></institution>
<addr-line><![CDATA[ Mexico City]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Hospital Infantil de México Federico Gómez Subdirección de Diagnóstico y Servicios Auxiliares ]]></institution>
<addr-line><![CDATA[ Mexico City]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2016</year>
</pub-date>
<volume>73</volume>
<numero>6</numero>
<fpage>405</fpage>
<lpage>410</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-11462016000600405&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-11462016000600405&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-11462016000600405&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: We present the case of a 2-year-old male patient with a facial tumor partially treated with chemotherapy before his admission to our institution. The tumor involved from the frontal region to the maxillary floor, the orbit, and the maxillary and sphenoid sinuses. The histopathological diagnosis revealed a stage IV alveolar rhabdomyosarcoma with infiltration to bone marrow and cerebrospinal fluid. He was managed with four cycles of adriamycin, actinomycin, cyclophosphamide and vincristine; cisplatin and irinotecan were added to the last cycle. The tumor had a 50% size reduction, but the patient died after a neutropenia and fever episode. The aggressive behavior of alveolar rhabdomyosarcoma has been associated with the expression of oncogenic fusion proteins resulting from chromosomal translocations, particularly t(2;13) (q35;q14) PAX3/FOXO1, and t(1;13) (p36;q14) PAX7/FOXO1 which were present in this patient.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: Se presenta el caso de un niño de dos años de edad con un tumor facial tratado parcialmente con quimioterapia anterior a su admisión en este hospital. El tumor abarcaba desde la región frontal hasta el piso maxilar, la órbita y los senos esfenoidales y maxilares. El diagnóstico histopatológico reveló un rabdomiosarcoma alveolar estadio IV con infiltración a la médula ósea y fluido cerebroespinal. El paciente fue tratado con cuatro ciclos de adriamicina, actinomicina, ciclofosfamida y vincristina; al último ciclo se añadieron cisplatino e irinotecan. El tumor se redujo en 50% de su tamaño, pero el paciente murió tras un episodio febril y neutropénico. La agresividad del rabdomiosarcoma alveolar se ha asociado con la expresión de proteínas oncogénicas de fusión provenientes de translocaciones cromosomales, particularmente t(2;13) (q35;q14) PAX3/FOXO1 y t(1;13) (p36;q14) PAX7/FOXO1, presentes en este paciente.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Rabdomiosarcoma]]></kwd>
<kwd lng="es"><![CDATA[Rabdomiosarcoma alveolar]]></kwd>
<kwd lng="es"><![CDATA[Infancia]]></kwd>
<kwd lng="es"><![CDATA[Translocación]]></kwd>
<kwd lng="es"><![CDATA[Significación pronóstica]]></kwd>
<kwd lng="en"><![CDATA[Rhabdomyosarcoma]]></kwd>
<kwd lng="en"><![CDATA[Alveolar rhabdomyosarcoma]]></kwd>
<kwd lng="en"><![CDATA[Childhood]]></kwd>
<kwd lng="en"><![CDATA[Translocation]]></kwd>
<kwd lng="en"><![CDATA[Prognostic significance]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Rhabdomyosarcoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paulino]]></surname>
<given-names><![CDATA[A.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Okcu]]></surname>
<given-names><![CDATA[M.F.]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Probl Cancer]]></source>
<year>2008</year>
<volume>32</volume>
<page-range>7-34</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[microRNAs and epigenetic mechanisms of rhabdomyosarcoma development]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ciesla]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Dulak]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Józkowicz]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Biochem Cell Biol]]></source>
<year>2014</year>
<volume>53</volume>
<page-range>482-92</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Classification of rhabdomyosarcoma and its molecular basis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parham]]></surname>
<given-names><![CDATA[D.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Barr]]></surname>
<given-names><![CDATA[F.G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Adv Anat Pathol]]></source>
<year>2013</year>
<volume>2</volume>
<page-range>387-97</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mechanisms of impaired differentiation in rhabdomyosarcoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keller]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Guttridge]]></surname>
<given-names><![CDATA[D.C.]]></given-names>
</name>
</person-group>
<source><![CDATA[FEBS J]]></source>
<year>2013</year>
<volume>280</volume>
<page-range>4323-34</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barr]]></surname>
<given-names><![CDATA[F.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Nauta]]></surname>
<given-names><![CDATA[L.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[R.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Schafer]]></surname>
<given-names><![CDATA[B.W.]]></given-names>
</name>
<name>
<surname><![CDATA[Nycum]]></surname>
<given-names><![CDATA[L.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Biegel]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Hum Mol Genet]]></source>
<year>1996</year>
<volume>5</volume>
<page-range>15-21</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sorensen]]></surname>
<given-names><![CDATA[P.H.]]></given-names>
</name>
<name>
<surname><![CDATA[Lynch]]></surname>
<given-names><![CDATA[J.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Qualman]]></surname>
<given-names><![CDATA[S.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Tirabosco]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[J.F.]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[H.M.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>2002</year>
<volume>20</volume>
<page-range>2672-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olanich]]></surname>
<given-names><![CDATA[M.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Barr]]></surname>
<given-names><![CDATA[F.G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Expert Opin Ther Targets]]></source>
<year>2013</year>
<volume>17</volume>
<page-range>607-23</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Gene fusion involving PAX3 and FOX family members in alveolar rhabdomyosarcoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barr]]></surname>
<given-names><![CDATA[F.G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Oncogene]]></source>
<year>2001</year>
<volume>20</volume>
<page-range>5736-46</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Alveolar rhabdomyosarcoma&#8212;the molecular drivers of PAX3/7-FOXO1 induced tumorigenesis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marshall]]></surname>
<given-names><![CDATA[A.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Grosveld]]></surname>
<given-names><![CDATA[G.C.]]></given-names>
</name>
</person-group>
<source><![CDATA[Skelet Muscle]]></source>
<year>2012</year>
<volume>2</volume>
<page-range>25-39</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Detection of fusion genes in formaln-fixed parafin-embedded tissue sections of rhabdomyosarcoma by RT-PCR and fluorescence in situ hybridization in Mexican patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eguía-Aguilar]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Ponce-Castañeda]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Najera-García]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Nieto-Martínez]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Kofman-Alfaro]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Sadowinski-Pine]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Med Res]]></source>
<year>2010</year>
<volume>41</volume>
<page-range>119-24</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a Children's Oncology Group Report]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skapek]]></surname>
<given-names><![CDATA[S.X.]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Barr]]></surname>
<given-names><![CDATA[F.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Bridge]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Gastier-Foster]]></surname>
<given-names><![CDATA[J.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Parham]]></surname>
<given-names><![CDATA[D.M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatr Blood Cancer]]></source>
<year>2013</year>
<volume>60</volume>
<page-range>1411-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bennicelli]]></surname>
<given-names><![CDATA[J.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Advani]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Schafer]]></surname>
<given-names><![CDATA[B.W.]]></given-names>
</name>
<name>
<surname><![CDATA[Barr]]></surname>
<given-names><![CDATA[F.G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Oncogene]]></source>
<year>1999</year>
<volume>18</volume>
<page-range>4348-56</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fredericks]]></surname>
<given-names><![CDATA[W.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Galili]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Mukhopadhyay]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Rovera]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Bennicelli]]></surname>
</name>
<name>
<surname><![CDATA[Barr]]></surname>
<given-names><![CDATA[F.G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Mol Cell Biol]]></source>
<year>1995</year>
<volume>15</volume>
<page-range>1522-35</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The oncogenic fusion protein PAX3-FKHR has a greater post-translational stability relative to PAX3 during early myogenesis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[P.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Hollenbach]]></surname>
<given-names><![CDATA[A.D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Biochim Biophys Acta]]></source>
<year>2007</year>
<volume>1770</volume>
<page-range>1450-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Regulation of the forkhead transcription factor FKHR, but no the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Del Peso]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[V.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Barr]]></surname>
<given-names><![CDATA[F.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Nuñez]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Oncogene]]></source>
<year>1999</year>
<volume>18</volume>
<page-range>7328-33</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[MicroRNA-29b: an emerging player in human cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Asian Pac J Cancer Prev]]></source>
<year>2014</year>
<volume>15</volume>
<page-range>9059-64</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[MicroRNA-29s could target AKT2 to inhibit gastric cancer cells invasion ability]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Jia]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<source><![CDATA[Med Oncol]]></source>
<year>2015</year>
<volume>32</volume>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Deregulation between miR-29b/c and DNMT3A is associated with epigenetic silencing of the CDH1 gene, affecting cell migration and invasion in gastric cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cui]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Gong]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS One]]></source>
<year>2015</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The role of miR-29b in cancer: regulation, function, and signaling]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[Q.]]></given-names>
</name>
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[F.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[Y.B.]]></given-names>
</name>
</person-group>
<source><![CDATA[Onco Targets Ther]]></source>
<year>2015</year>
<volume>8</volume>
<page-range>539-48</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aroeira]]></surname>
<given-names><![CDATA[L.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilera]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Tomero]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Bajo]]></surname>
<given-names><![CDATA[M.A.]]></given-names>
</name>
<name>
<surname><![CDATA[del Peso]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez-Heffernan]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2007</year>
<volume>18</volume>
<page-range>2004-13</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meng]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Henson]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Lang]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Wehbe]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Maheshwari]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Mendell]]></surname>
<given-names><![CDATA[J.T.]]></given-names>
</name>
</person-group>
<source><![CDATA[Gastroenterology]]></source>
<year>2006</year>
<volume>130</volume>
<page-range>2113-29</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crist]]></surname>
<given-names><![CDATA[W.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Garnsey]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Beltangady]]></surname>
<given-names><![CDATA[M.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Ruymann]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Webber]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Hays]]></surname>
<given-names><![CDATA[D.M.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>1990</year>
<volume>8</volume>
<page-range>443-52</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pappo]]></surname>
<given-names><![CDATA[A.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Etcubanas]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Santana]]></surname>
<given-names><![CDATA[V.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[B.N.]]></given-names>
</name>
<name>
<surname><![CDATA[Kun]]></surname>
<given-names><![CDATA[L.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Fontanesi]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer]]></source>
<year>1993</year>
<volume>71</volume>
<page-range>2119-25</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cyclophosphamide dose intensi&#64257;cation during induction therapy for intermediate risk pediatric rhabdomyosarcoma is feasible but does not improve outcome. A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spunt]]></surname>
<given-names><![CDATA[S.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[L.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ruymann]]></surname>
<given-names><![CDATA[F.B.]]></given-names>
</name>
<name>
<surname><![CDATA[Qualman]]></surname>
<given-names><![CDATA[S.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Donaldson]]></surname>
<given-names><![CDATA[S.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodeberg]]></surname>
<given-names><![CDATA[D.A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2004</year>
<volume>10</volume>
<page-range>6072-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study IV]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Breneman]]></surname>
<given-names><![CDATA[J.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Lyden]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Pappo]]></surname>
<given-names><![CDATA[A.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Link]]></surname>
<given-names><![CDATA[M.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[J.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Pharman]]></surname>
<given-names><![CDATA[D.M.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>2003</year>
<volume>21</volume>
<page-range>78-84</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
